The disconnect between phase II and phase III trials of drugs for heart failure (Q38072257)

28 August 2017

1 reference

title

The disconnect between phase II and phase III trials of drugs for heart failure (English)

1 reference

28 August 2017

main subject

phase III clinical trial

0 references

phase II clinical trial

0 references

0 references

4

Mihai Gheorghiade

1 reference

28 August 2017

5

Javed Butler

1 reference

28 August 2017

Muthiah Vaduganathan

1

1 reference

28 August 2017

Stephen J Greene

series ordinal

2

1 reference

28 August 2017

Andrew P Ambrosy

series ordinal

3

1 reference

28 August 2017

language of work or name

English

0 references

publication date

8 January 2013

1 reference

Nature Reviews Cardiology

28 August 2017

published in

1 reference

28 August 2017

volume

10

1 reference

28 August 2017

issue

2

1 reference

28 August 2017

page(s)

85-97

1 reference

Rehospitalizations among patients in the Medicare fee-for-service program

28 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2012.181

National and regional trends in heart failure hospitalization and mortality rates for Medicare beneficiaries, 1998-2008

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2012.181

Characteristics, treatments, and outcomes of patients with preserved systolic function hospitalized for heart failure: a report from the OPTIMIZE-HF Registry

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2012.181

Thirty-day readmissions--truth and consequences

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2012.181

Trends in length of stay and short-term outcomes among Medicare patients hospitalized for heart failure, 1993-2006.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2012.181

Early and long-term outcomes of heart failure in elderly persons, 2001-2005.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2012.181

Association between performance measures and clinical outcomes for patients hospitalized with heart failure

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2012.181

Acute heart failure syndromes: current state and framework for future research

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2012.181

Postdischarge Assessment After a Heart Failure Hospitalization

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2012.181

Heart failure: Early follow-up after hospitalization for heart failure

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2012.181

A comprehensive, longitudinal description of the in-hospital and post-discharge clinical, laboratory, and neurohormonal course of patients with heart failure who die or are re-hospitalized within 90 days: analysis from the EVEREST trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2012.181

Clinical trials of pharmacological therapies in acute heart failure syndromes: lessons learned and directions forward

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2012.181

Phase III clinical trial end points in acute heart failure syndromes: A virtual roundtable with the acute heart failure syndromes international working group

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2012.181

Causes of death and rehospitalization in patients hospitalized with worsening heart failure and reduced left ventricular ejection fraction: results from Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study with Tolvaptan (EVEREST) progr

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2012.181

The association between hospital volume and processes, outcomes, and costs of care for congestive heart failure

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2012.181

Recent national trends in readmission rates after heart failure hospitalization

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2012.181

Outcome of heart failure with preserved ejection fraction in a population-based study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2012.181

Pharmacology of new agents for acute heart failure syndromes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2012.181

Hemodynamic and neurohumoral effects of continuous infusion of levosimendan in patients with congestive heart failure.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2012.181

Acute hemodynamic and clinical effects of levosimendan in patients with severe heart failure. Study Investigators

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2012.181

Safety and efficacy of a novel calcium sensitizer, levosimendan, in patients with left ventricular failure due to an acute myocardial infarction. A randomized, placebo-controlled, double-blind study (RUSSLAN).

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2012.181

Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomised double-blind trial.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2012.181

Clinical trials update from the American Heart Association: REPAIR-AMI, ASTAMI, JELIS, MEGA, REVIVE-II, SURVIVE, and PROACTIVE.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2012.181

Clinical trials update and cumulative meta-analyses from the American College of Cardiology: WATCH, SCD-HeFT, DINAMIT, CASINO, INSPIRE, STRATUS-US, RIO-Lipids and cardiac resynchronisation therapy in heart failure

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2012.181

Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE Randomized Trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2012.181

Neurohumoral Activation and Ventricular Arrhythmias in Patients with Decompensated Congestive Heart Failure:

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2012.181

Neurohormonal prediction of mortality following admission for decompensated heart failure

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2012.181

Clinical trials update: highlights of the scientific sessions of the XXIII Congress of the European Society of Cardiology--WARIS II, ESCAMI, PAFAC, RITZ-1 and TIME

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2012.181

Hemodynamic and clinical effects of tezosentan, an intravenous dual endothelin receptor antagonist, in patients hospitalized for acute decompensated heart failure

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2012.181

RITZ-5: randomized intravenous TeZosentan (an endothelin-A/B antagonist) for the treatment of pulmonary edema: a prospective, multicenter, double-blind, placebo-controlled study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2012.181

Tezosentan in patients with acute heart failure and acute coronary syndromes: results of the Randomized Intravenous TeZosentan Study (RITZ-4).

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2012.181

The hemodynamic and neurohormonal effects of low doses of tezosentan (an endothelin A/B receptor antagonist) in patients with acute heart failure

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2012.181

Effects of tezosentan on symptoms and clinical outcomes in patients with acute heart failure: the VERITAS randomized controlled trials

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2012.181

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2012.181

Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure. A substudy of the Studies of Left Ventricular Dysfunction (SOLVD)

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2012.181

Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: a randomized controlled trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2012.181

Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST Clinical Status Trials

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2012.181

Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2012.181

Acute hemodynamic effects of tolvaptan, a vasopressin V2 receptor blocker, in patients with symptomatic heart failure and systolic dysfunction: an international, multicenter, randomized, placebo-controlled trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2012.181

Adenosine and kidney function.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2012.181

Plasma adenosine levels increase in patients with chronic heart failure

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2012.181

Incidence, predictors at admission, and impact of worsening renal function among patients hospitalized with heart failure

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2012.181

Risk stratification for in-hospital mortality in acutely decompensated heart failure: classification and regression tree analysis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2012.181

Renal impairment and outcomes in heart failure: systematic review and meta-analysis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2012.181

The effects of KW-3902, an adenosine A1-receptor antagonist,on diuresis and renal function in patients with acute decompensated heart failure and renal impairment or diuretic resistance

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2012.181

The effect of KW-3902, an adenosine A1 receptor antagonist, on renal function and renal plasma flow in ambulatory patients with heart failure and renal impairment

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2012.181

The PROTECT pilot study: a randomized, placebo-controlled, dose-finding study of the adenosine A1 receptor antagonist rolofylline in patients with acute heart failure and renal impairment

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2012.181

Rolofylline, an adenosine A1-receptor antagonist, in acute heart failure

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2012.181

Systemic hemodynamic, neurohormonal, and renal effects of a steady-state infusion of human brain natriuretic peptide in patients with hemodynamically decompensated heart failure

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2012.181

New and emerging drug therapies for the management of acute heart failure.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2012.181

Hemodynamic effects of a single intravenous injection of synthetic human brain natriuretic peptide in patients with heart failure secondary to ischemic or idiopathic dilated cardiomyopathy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2012.181

Hemodynamic and renal excretory effects of human brain natriuretic peptide infusion in patients with congestive heart failure. A double-blind, placebo-controlled, randomized crossover trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2012.181

Sustained hemodynamic effects of an infusion of nesiritide (human b-type natriuretic peptide) in heart failure: a randomized, double-blind, placebo-controlled clinical trial. Natrecor Study Group

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2012.181

Intravenous nesiritide, a natriuretic peptide, in the treatment of decompensated congestive heart failure. Nesiritide Study Group.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2012.181

Intravenous nesiritide vs nitroglycerin for treatment of decompensated congestive heart failure: a randomized controlled trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2012.181

Short-term risk of death after treatment with nesiritide for decompensated heart failure: a pooled analysis of randomized controlled trials

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2012.181

Risk of worsening renal function with nesiritide in patients with acutely decompensated heart failure

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2012.181

Effect of nesiritide in patients with acute decompensated heart failure

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2012.181

European experience on the practical use of levosimendan in patients with acute heart failure syndromes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2012.181

Heart failure etiology and response to milrinone in decompensated heart failure: results from the OPTIME-CHF study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2012.181

Improving postdischarge outcomes in patients hospitalized for acute heart failure syndromes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2012.181

Beyond dyspnoea as an endpoint in acute heart failure trials

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2012.181

The impact of early standard therapy on dyspnoea in patients with acute heart failure: the URGENT-dyspnoea study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2012.181

A proposal to standardize dyspnoea measurement in clinical trials of acute heart failure syndromes: the need for a uniform approach

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2012.181

Effects of tolvaptan on dyspnoea relief from the EVEREST trials

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2012.181

Weight changes after hospitalization for worsening heart failure and subsequent re-hospitalization and mortality in the EVEREST trial.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2012.181

Systolic blood pressure at admission, clinical characteristics, and outcomes in patients hospitalized with acute heart failure

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2012.181

Multicenter, randomized, double-blind, placebo-controlled study on the effect of oral tolvaptan on left ventricular dilation and function in patients with heart failure and systolic dysfunction

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2012.181

Changes in renal function during hospitalization and soon after discharge in patients admitted for worsening heart failure in the placebo group of the EVEREST trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2012.181

Relaxin for the treatment of patients with acute heart failure (Pre-RELAX-AHF): a multicentre, randomised, placebo-controlled, parallel-group, dose-finding phase IIb study.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2012.181

Acute heart failure syndromes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2012.181

Characteristics and outcomes of patients hospitalized for heart failure in the United States: rationale, design, and preliminary observations from the first 100,000 cases in the Acute Decompensated Heart Failure National Registry (ADHERE).

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2012.181

The EuroHeart Failure survey programme-- a survey on the quality of care among patients with heart failure in Europe. Part 1: patient characteristics and diagnosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2012.181

Cinaciguat, a soluble guanylate cyclase activator: results from the randomized, controlled, phase IIb COMPOSE programme in acute heart failure syndromes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2012.181

Review of current and investigational pharmacologic agents for acute heart failure syndromes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2012.181

Bayesian adaptive trial design in acute heart failure syndromes: moving beyond the mega trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2012.181

Heart disease and stroke statistics--2012 update: a report from the American Heart Association

31 March 2020

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/23296069

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

2009 focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/23296069

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1038/NRCARDIO.2012.181

1 reference

Dimensions Publication ID

28 August 2017

1025350324

0 references

1 reference